Eribulin mesylate

Nature Reviews Drug Discovery

Volumn 10, Issue 3, 2011, Pages 173-174

  Huyck, Timothy K ^a   Gradishar, William ^a   Manuguid, Fil ^b   Kirkpatrick, Peter ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; ERIBULIN; FLUOROURACIL; GEMCITABINE; HALAVEN; HALICHONDRIN B; IXABEPILONE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG APPROVAL; ETHERS, CYCLIC; FEMALE; FURANS; HUMANS; KETONES; MESYLATES; MICROTUBULES; NEOPLASM METASTASIS;

EID: 79952175766     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3389     Document Type: Article

References (16)

1. Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Rev. Drug Discov. 9, 790-803 (2010).
2. Jackson, K. L. et al. The halichondrins and E7389. Chem. Rev. 109, 3044-3079 (2009).
3. Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013-1021 (2001). (Pubitemid 32174419)
4. Seletsky, B. M. et al. Structurally simplified macrolactone analogues of halichondrin B. Bioorg. Med. Chem. Lett. 14, 5547-5550 (2004). (Pubitemid 39346342)
5. Kuznetsov, G. et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 64, 5760-5766 (2004). (Pubitemid 39095575)
6. Jordan, M. A. et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086-1095 (2005). (Pubitemid 41079102)
7. Dabydeen, D. A. et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol. Pharmacol. 70, 1866-1875 (2006). (Pubitemid 44771902)
8. US Food and Drug Administration. FDA labelling information - Halaven. FDA website [online], http:// www.accessdata.fda.gov/drugsatfda-docs/ label/2010/201532lbl.pdf (2010).
9. Cortes, J. et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 28, 3922-3928 (2010).
10. Twelves, C. et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin. Breast Cancer 10, 160-163 (2010).
11. American Cancer Society. Cancer facts and figures 2010. ACS website [online] http://www.cancer.org/acs/ groups/content/@epidemiologysurveilance/ documents/ document/acspc-026238.pdf. (2010).
12. Beslija, S. et al. Third consensus on medical treatment of metastatic breast cancer. Ann. Oncol. 20, 1771-1785 (2009).
13. Dufresne, A. et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res. Treat. 107, 275-279 (2008). (Pubitemid 350265698)
14. Moreno-Aspitia, A. & Perez, E. A. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin. Proc. 84, 533-545 (2009).
15. Onozuka, M. Japan Equity Research (26 Jan 2011).
16. Sakai, F. & Tateno, T. Credit Suisse Asia Pacific/Japan Equity Research (26 Jan 2011).